13 citations
,
July 2019 in “Toxicology research” Ethanamizuril is safe for rats at 20 mg/kg feed, but higher doses cause hair loss, organ changes, and liver, kidney, and lung damage.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
December 2022 in “Archives of Dermatological Research” Adding cetirizine to minoxidil improves hair growth and thickness in women with androgenetic alopecia.
July 2025 in “Indian Dermatology Online Journal” Switching insulin brands caused skin lesions in a diabetic woman, resolved by changing to oral medication.
6 citations
,
November 1999 in “Mycoses” A man in Japan got better from a scalp fungal infection using terbinafine.
CG2001 is safe, well-tolerated, and a promising treatment for hair loss with fewer side effects.
November 2001 in “Oncology Times” The committee decided not to approve the drug due to low effectiveness and high risks.
6 citations
,
July 2016 in “Doklady Biochemistry and Biophysics” GD-23 reduces anxiety by relying on neurosteroid production.
January 2025 in “il Diabete” Targeted drug delivery to pancreatic beta-cells can improve type 2 diabetes treatment.
2 citations
,
June 2005 in “Clinical Oncology” A man's bald spot grew hair after starting cancer treatment with gefitinib.
2 citations
,
November 2023 in “Bioactive materials” New method improves copper peptide delivery for hair growth three times better than current options.
November 2025 in “Drug Delivery and Translational Research” 4 citations
,
April 2024 in “Journal of Drugs in Dermatology” Ruxolitinib cream may help treat severe hair loss in children.
9 citations
,
September 2017 in “PubMed” EGFR inhibitors can cause skin issues, but managing them is important for treatment success.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
43 citations
,
July 2017 in “International journal of pharmaceutics” Using β-cyclodextrin derivatives improves the solubility and bioavailability of steroidal drugs.
March 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
5 citations
,
May 2019 in “Journal of the European Academy of Dermatology and Venereology” Prostaglandin analogue may help with eyebrow loss in frontal fibrosing alopecia.
1 citations
,
July 2023 in “Cureus” Cetosomal minoxidil alone and with finasteride is effective and well-tolerated for hair loss treatment.
June 2019 in “International journal of dermatology and venereology” A man developed skin issues from cancer medication, which improved with specific treatments.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
4 citations
,
December 2024 in “Gels” The gel effectively delivers drugs to the eye, fights bacteria, and protects against oxidative stress.
2 citations
,
August 2023 in “Molecules” SH-340 may improve skin barrier and help treat atopic dermatitis.
January 2022 in “SSRN Electronic Journal” Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.
April 2025 in “JAAD Case Reports” Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
116 citations
,
December 2003 in “Acta Dermato Venereologica” Iressa often causes skin issues like acne and dryness in lung cancer patients.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.